Prognostic significance of 1-year versus baseline high-sensitivity C-reactive protein after acute myocardial infarction: nationwide landmark results

Figures

• 

  Figure 1. Study flow. In total, 29,625 patients with AMI undergoing PCI were enrolled from two nationwide registries: the KAMIR-NIH (2011–2015) and KAMIR-V (2015–2020). AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; hs-CRP, high-sensitivity C-reactive protein; MACE, major adverse cardiovascular events; F/U, follow-up.

• 

  Figure 2. Time-dependent prognostic value of hs-CRP after AMI. Kaplan–Meier curves stratified by baseline hs-CRP (≥ 2 mg/L vs. < 2 mg/L) illustrating cumulative incidence of (A) all-cause death, (B) MACE, (C) cardiovascular death. Curves compare outcomes by baseline hs-CRP using a prespecified landmark at 1-year post–index procedure. MACE was defined as a composite of cardiovascular death, MI, stroke, repeat revascularization, and stent thrombosis. p values are from log-rank tests; HRs with 95% CIs were estimated using Cox models as specified in the Methods. HR, hazard ratio; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; MACE, major adverse cardiovascular events; AMI, acute myocardial infarction; MI, myocardial infarction.

• 

  Figure 3. Time-dependent prognostic value of 1-year hs-CRP beyond 1 year. Kaplan–Meier curves stratified by 1-year hs-CRP (≥ 2 mg/L vs. < 2 mg/L) illustrating cumulative incidence of (A) all-cause death, (B) MACE, (C) cardiovascular death beyond 1 year. Panels compare outcomes by 1-year hs-CRP, with follow-up beginning at 1-year. MACE was defined as a composite of cardiovascular death, MI, stroke, repeat revascularization, and stent thrombosis. p values are from log-rank tests; HRs with 95% CIs were estimated using Cox models as specified in the Methods. HR, hazard ratio; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; MACE, major adverse cardiovascular events; MI, myocardial infarction.

• 

  Figure 4. Cumulative incidence of clinical outcomes stratified by baseline and 1-year hs-CRP levels (≥ 2 mg/L vs. < 2 mg/L). Cumulative incidence of MACE at 3 years based on hs-CRP trajectory: low (baseline) → low (at 1 year), low → high, high → low, high → high, beginning at 1 year post-index procedure. Patients who experienced events within the first year were excluded. HR, hazard ratio; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; MACE, major adverse cardiovascular events.

•